An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis
- PMID: 15343380
- PMCID: PMC514591
- DOI: 10.1172/JCI22087
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis
Abstract
A mouse model involving the human papillomavirus type-16 oncogenes develops cervical cancers by lesional stages analogous to those in humans. In this study the angiogenic phenotype was characterized, revealing intense angiogenesis in high-grade cervical intraepithelial neoplasias (CIN-3) and carcinomas. MMP-9, a proangiogenic protease implicated in mobilization of VEGF, appeared in the stroma concomitant with the angiogenic switch, expressed by infiltrating macrophages, similar to what has been observed in humans. Preclinical trials sought to target MMP-9 and angiogenesis with a prototypical MMP inhibitor and with a bisphosphonate, zoledronic acid (ZA), revealing both to be antiangiogenic, producing effects comparable to a Mmp9 gene KO in impairing angiogenic switching, progression of premalignant lesions, and tumor growth. ZA therapy increased neoplastic epithelial and endothelial cell apoptosis without affecting hyperproliferation, indicating that ZA was not antimitotic. The analyses implicated cellular and molecular targets of ZA's actions: ZA suppressed MMP-9 expression by infiltrating macrophages and inhibited metalloprotease activity, reducing association of VEGF with its receptor on angiogenic endothelial cells. Given its track record in clinical use with limited toxicity, ZA holds promise as an "unconventional" MMP-9 inhibitor for antiangiogenic therapy of cervical cancer and potentially for additional cancers and other diseases where MMP-9 expression by infiltrating macrophages is evident.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/514591/bin/JCI0422087.f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/514591/bin/JCI0422087.f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/514591/bin/JCI0422087.f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/514591/bin/JCI0422087.f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/514591/bin/JCI0422087.f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/514591/bin/JCI0422087.f6.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/514591/bin/JCI0422087.f7.gif)
Similar articles
-
Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.Oncotarget. 2017 Jan 3;8(1):118-132. doi: 10.18632/oncotarget.9497. Oncotarget. 2017. PMID: 27223431 Free PMC article.
-
[Remodeling of angiogenesis and lymphangiogenesis in cervical cancer development].Biomed Khim. 2015 Sep-Oct;61(5):579-97. doi: 10.18097/PBMC20156105579. Biomed Khim. 2015. PMID: 26539865 Review. Russian.
-
Antiangiogenic effects of zoledronate on cancer neovasculature.Future Oncol. 2011 Nov;7(11):1325-33. doi: 10.2217/fon.11.113. Future Oncol. 2011. PMID: 22044205 Review.
-
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.Cancer Immunol Immunother. 2008 Oct;57(10):1451-9. doi: 10.1007/s00262-008-0482-9. Epub 2008 Feb 23. Cancer Immunol Immunother. 2008. PMID: 18297280 Free PMC article.
-
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.Cancer Res. 2007 Dec 1;67(23):11438-46. doi: 10.1158/0008-5472.CAN-07-1882. Cancer Res. 2007. PMID: 18056472 Free PMC article.
Cited by
-
Identification of key eRNAs for intervertebral disc degeneration by integrated multinomial bioinformatics analysis.BMC Musculoskelet Disord. 2024 May 4;25(1):356. doi: 10.1186/s12891-024-07438-6. BMC Musculoskelet Disord. 2024. PMID: 38704519 Free PMC article.
-
Dynamic interactions in the tumor niche: how the cross-talk between CAFs and the tumor microenvironment impacts resistance to therapy.Front Mol Biosci. 2024 Feb 22;11:1343523. doi: 10.3389/fmolb.2024.1343523. eCollection 2024. Front Mol Biosci. 2024. PMID: 38455762 Free PMC article. Review.
-
Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy.Pharmaceutics. 2023 Dec 29;16(1):61. doi: 10.3390/pharmaceutics16010061. Pharmaceutics. 2023. PMID: 38258072 Free PMC article. Review.
-
Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma.Hepatol Int. 2024 Feb;18(1):73-90. doi: 10.1007/s12072-023-10615-9. Epub 2023 Dec 30. Hepatol Int. 2024. PMID: 38159218
-
Research progress on the role of tumor‑associated macrophages in tumor development and their use as molecular targets (Review).Int J Oncol. 2024 Feb;64(2):11. doi: 10.3892/ijo.2023.5599. Epub 2023 Dec 8. Int J Oncol. 2024. PMID: 38063203 Free PMC article. Review.
References
-
- Waggoner SE. Cervical cancer. Lancet. 2003;361:2217–2225. - PubMed
-
- Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994;54:800–804. - PubMed
-
- Smith-McCune K, Zhu YH, Hanahan D, Arbeit J. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res. 1997;57:1294–1300. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous